Retrospect and prospect on biological products for immunological prevention, therapy and diagnosis of tuberculosis in China

doi:10.3969/j.issn.1000-6621.2019.11.002

Abstract

Abstract:

Immunological prevention, treatment and diagnosis of tuberculosis is one of the most necessary measures to control tuberculosis. This paper summarizes the development, research status and future development direction of tuberculosis-related biological products in China, and then prospects the organic use of various biological products under the framework of the established tuberculosis immune prevention system to reduce the rate of tuberculosis infection and incidence, as well as the possibility of changing the status quo of high burden of tuberculosis in China.

Key words: Tuberculosis, Immunologic techniques, Protective agents, Diagnosis, Therapeutic uses

ZHAO Ai-hua,WANG Guo-zhi,XU Miao. Retrospect and prospect on biological products for immunological prevention, therapy and diagnosis of tuberculosis in China[J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1149-1154. doi: 10.3969/j.issn.1000-6621.2019.11.002

References 34

[1]	World Health Organization . Global tuberculosis report 2018. Geneva: World Health Organization, 2018. doi: 10.1080/21645515.2019.1693720 URL pmid: 31730397
[2]	Abubakar I, Pimpin L, Ariti C , et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess, 2013, 17(37): 1-372, v-vi. doi: 10.3310/hta17370 URL pmid: 24021245
[3]	徐苗, 罗永艾, 陈保文 , 等. 无细胞耻垢分枝杆菌疫苗对结核杆菌感染者的预防作用研究. 药品评价, 2006,3(2):102-104.
[4]	徐苗, 陈保文, 沈小兵 , 等. 耻垢分枝杆菌作为免疫调节剂的研究. 中华微生物学和免疫学杂志, 2005,25(9):752-755.
[5]	Schrager LK, Chandrasekaran P, Fritzell BH , et al. WHO preferred product characteristics for new vaccines against tuberculosis. Lancet Infect Dis, 2018,18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3 URL pmid: 30064668
[6]	Perez-Martinez AP, Ong E, Zhang L , et al. Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa. Infect Genet Evol, 2017,55:244-250. doi: 10.1016/j.meegid.2017.09.023 URL pmid: 28941991
[7]	Orr MT, Beebe EA, Hudson TE , et al. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One, 2014,9(1):e83884. doi: 10.1371/journal.pone.0083884 URL pmid: 24404140
[8]	徐苗, 邓海清, 陈保文 , 等. 初免加强型结核疫苗保护力评价用动物模型的建立. 中华微生物学与免疫学杂志, 2013,33(12):893-899.
[9]	Tameris MD, Hatherill M, Landry BS , et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, 2013,381(9871):1021-1028. doi: 10.1016/S0140-6736(13)60177-4 URL
[10]	Kashangura R, Jullien S, Garner P , et al. MVA85A vaccine to enhance BCG for preventing tuberculosis. Cochrane Database Syst Rev, 2019, 4: CD012915. doi: 10.1002/14651858.CD011260.pub2 URL pmid: 31801180
[11]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[12]	全国微卡菌苗临床研究协作组. 母牛分支杆菌菌苗在初治肺结核治疗中的作用. 中华结核和呼吸杂志, 2001,24(1):44-47.
[13]	卢水华, 刘志成, 陈绪汉 , 等. 母牛分支杆菌菌苗免疫治疗肺结核的临床观察. 中国防痨杂志, 1998,20(3):123-126.
[14]	卢水华, 刘志成, 陈绪汉 , 等. 母牛分支杆菌菌苗免疫治疗肺结核临床观察——2年随访结果. 中国防痨杂志, 2002,24(6):324-326.
[15]	王继业, 林定文 . 母牛分枝杆菌菌苗在耐多药肺结核治疗中的作用. 华夏医学, 2006,19(3):443-445.
[16]	彭丽, 陈保文, 罗永艾 , 等. 利用噬菌体杀灭巨噬细胞内耻垢分枝杆菌的实验研究. 中华结核和呼吸杂志, 2005,28(9):619-622.
[17]	潘欣, 张立兴, 王国治 , 等. 结核分支杆菌噬菌体分型在北京地区的应用. 中国防痨杂志, 1991,13(4):171-173.
[18]	Peng L, Chen BW, Luo YA , et al. Effect of mycobacteriophage to intracellular mycobateria in vitro. Chin Med J(Engl), 2006,119(8):692-695. URL pmid: 16635416
[19]	彭丽, 陈保文, 罗永艾 , 等. 噬菌体D29对耐药结核病豚鼠的治疗作用. 第四军医大学学报, 2009,30(17):1576-1579.
[20]	彭丽, 罗永艾, 陈保文 , 等. 噬菌体D29对感染敏感株结核分枝杆菌豚鼠的疗效. 中国人兽共患病学报, 2009,25(8):733-736.
[21]	Pai M, Denkinger CM, Kik SV , et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014,27(1):3-20. doi: 10.1128/CMR.00034-13 URL
[22]	陈红兵, 张小刚, 何秀云 , 等. 结核分支杆菌重组38kDa蛋白质抗原免疫学特性的研究. 中国现代医学杂志, 2005,15(6):837-839.
[23]	赵海 . 牛分枝杆菌主要分泌性蛋白70和脂蛋白83的克隆表达及抗原性研究. 北京: 军事医学科学院, 2010.
[24]	周搏 . 牛结核分枝杆菌Cfp10-Esat6 的融合表达及其检测的研究. 长春: 吉林大学, 2009.
[25]	徐苗, 罗永艾, 黎友伦 , 等. 重组结核分枝杆菌11000蛋白对结核分枝杆菌感染的鉴别作用. 中华结核和呼吸杂志, 2006,29(11):762-765.
[26]	Wu X, Yang Y, Zhang J , et al. Humoral immune responses against the Mycobacterium tuberculosis 38-kilodalton, MTB48, and CFP-10/ESAT-6 antigens in tuberculosis. Clin Vaccine Immunol, 2010,17(3):372-375. doi: 10.1128/CVI.00287-09 URL pmid: 20053875
[27]	赵淑娟, 李春, 关永春 , 等. 重组结核分枝杆菌11kDa蛋白皮肤试验与结核菌素皮肤试验的比较研究. 医学综述, 2017,23(20):4146-4149.
[28]	吴雪琼, 蔡小波, 张俊仙 , 等 . 结核分枝杆菌特异性融合蛋白及其编码基因与应用: 中国, CN201610011926.X. 2016 -04-27.
[29]	Li F, Xu M, Zhou L , et al. Safety of recombinant fusion protein ESAT6-CFP10 as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, single-center phase Ⅰ clinical trial. Clin Vaccine Immunol, 2016,23(9):767-773. doi: 10.1128/CVI.00154-16 URL pmid: 27413070
[30]	Li F, Xu M, Qin C , et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10): 889. e9- 889. e16. doi: 10.1016/j.cmi.2016.07.015 URL pmid: 27451942
[31]	陈保文, 沈小兵, 苏城 , 等. 荚膜组织胞浆菌素纯蛋白衍生物的制备. 中国生物制品学杂志, 2006,19(6):617-618, 622.
[32]	王璞, 陈保文, 罗永艾 , 等. ELISA检测抗荚膜组织胞浆菌抗体方法的建立. 临床检验杂志, 2007,25(2):87-89.
[33]	李凤祥, 徐苗, 陈保文 , 等. P-HTPM对荚膜组织胞浆菌和不同分枝杆菌致敏豚鼠的皮肤试验. 中国生物制品学杂志, 2008,21(10):890-892.
[34]	郭天芳, 王璞, 陈保文 , 等. 荚膜组织胞浆菌病诊断及与结核病鉴别诊断方法的实验研究. 中国感染与化疗杂志, 2016,16(2):200-204.